home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Upstream Bioprocessing: DoE Optimization for CHO Cell Cultures

 
  January 24, 2024  
     
 
Xtalks, Online
2024-02-27


Chinese hamster ovary (CHO) cells are commonly used in bioprocessing to express desired proteins, including antibody, peptide and other protein-based therapeutics, at high titers. In upstream bioprocessing, process optimization and scale-up have presented challenges, and design of experiments (DoE) methodologies can alleviate these challenges and lay the foundation for a robust and scalable cell culture process.

Join this webinar to learn about upstream process development experiments conducted with MilliporeSigma across several CHOZN® cell lines at Culture Biosciences’ South San Francisco cell culture facility.

CHOZN® cell lines were evaluated with combinations of two batch media and three feed media variations in proprietary 250mL mammalian bioreactors for optimal combinations. The effect of each media combination on each cell line was evaluated for various quality attributes, including cell growth, lactate production and final immunoglobulin G (IgG) production. The proprietary purpose-built bioreactors were used to evaluate large-scale DoE experiments. Statistical analyses were performed to determine the effect of each component on the system. This work identified a significant increase in the final titer for two CHOZN® cell lines utilizing the same feed media. MilliporeSigma successfully validated these small-scale results at a 3 L scale, indicating the scalability of this mammalian cell culture process.

Join this webinar to learn how DoE optimization strategies set the foundation for robust upstream bioprocessing.

Keywords: Biomanufacturing, CDMO/CMO, Cell & Gene Therapies, AAV, Chinese Hamster Ovary, Bioprocess Development, Biologics Manufacturing, Protein Therapeutic, Antibody-Drug Conjugate, Monoclonal Antibodies, Antibodies, Process Development, Biosimilars, Cell Culture, Biologics, Antibody, Biosimilar, Drug Development, Gene Therapy
 
 
Organized by: Xtalks
Invited Speakers: Jean-Marc Guedon, Director of Application Technologies, Culture Biosciences
 
Deadline for Abstracts: 2024-02-27
 
Registration: Free Registration
E-mail: tristan@xtalks.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.